As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.
Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Senior Project Manager, EURORDIS
Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Suneet Varma, Global President, Rare Disease, Pfizer
Tomislav Sokol, Member of European Parliament
The podcast Science Will Win is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.